Parkinson's Disease: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
Parkinson’s disease, also known as hypokinetic rigid syndrome (HRS), is an [[Idiopathic|idiopathic]] and has no known cause. It is normally due to the degeneration of [[Dopaminergic neurone|dopaminergic neurones]] of the nigrostriatal tract and loss of DA neurotransmission in the striatum. The symptoms of this disease are a resting tremor, muscle rigidity and suppression of voluntary movements (hypokinesis). In the later stages, mental and behavioural problems may occur such as depression and even dementia. | Parkinson’s disease, also known as hypokinetic rigid syndrome (HRS), is an [[Idiopathic|idiopathic]] and has no known cause. It is normally due to the degeneration of [[Dopaminergic neurone|dopaminergic neurones]] of the nigrostriatal tract and loss of [[Dopamine|dopamine]] (DA) neurotransmission in the striatum. The symptoms of this disease are a resting tremor, muscle rigidity and suppression of voluntary movements (hypokinesis). In the later stages, mental and behavioural problems may occur such as depression and even dementia. | ||
The main 4 dopaminergic pathways are:- | The main 4 dopaminergic pathways are:- | ||
Revision as of 17:55, 18 October 2015
Parkinson’s disease, also known as hypokinetic rigid syndrome (HRS), is an idiopathic and has no known cause. It is normally due to the degeneration of dopaminergic neurones of the nigrostriatal tract and loss of dopamine (DA) neurotransmission in the striatum. The symptoms of this disease are a resting tremor, muscle rigidity and suppression of voluntary movements (hypokinesis). In the later stages, mental and behavioural problems may occur such as depression and even dementia.
The main 4 dopaminergic pathways are:-
- Nigrostriatal - Substantia nigra to striatum
- Striatum Mesolimbic - Ventral tegmental area to nucleus accumbens
- Mesocortical - Ventral tegmental area to frontal cortex
- Frontal cortex Tuberoinfundibular - Arcuate nucleus to pituitary gland
The decarboxylase inhibitor – carbidopa, the MAO inhibitor: Selegiline and D2 receptor agonists like Bromocriptine can be used to treat Parkinson’s disease.